Breast cancer metastasis: mapping long term outcomes in Australia

Andrew Redfern and Hilary Martin
Med J Aust 2022; 217 (8): . || doi: 10.5694/mja2.51728
Published online: 17 October 2022

Characterising the ongoing but changing risk of relapse after breast cancer diagnosis improves surveillance planning and patient care

The high incidence of breast cancer and the enduring risk of relapse are major burdens for oncology care. Defining individual recurrence risk profiles would help optimise resource use when managing patients with breast cancer, but population‐based outcomes datasets are unfortunately scarce.

  • 1 The University of Western Australia, Perth, WA
  • 2 Fiona Stanley Hospital, Perth, WA

Competing interests:

No relevant disclosures.

  • 1. Lord SJ, Daniels B, Kiely BE, et al. Long term risk of distant metastasis in women with non‐metastatic breast cancer and survival after metastasis detection: a population‐based linked health records study. Med J Aust 2022; 217: 402‐409.
  • 2. Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomized trials. Lancet 2005; 365: 1687–1717.
  • 3. Lohrisch C, Francl M, Sun S, et al. Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians’ practices around seeking biopsy at the time of breast cancer relapse. Breast Cancer Res Treat 2018; 168: 221–228.
  • 4. Mejri N, Boussen H, Labidi S, et al. Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient’s follow up? Ther Adv Med Oncol 2015; 7: 144‐152.
  • 5. Luen SJ. Clinical implications of genomic driver alterations in hormone receptor‐positive, human epidermal growth factor receptor (HER) 2‐negative early breast cancer [doctoral thesis]. University of Melbourne, 2021. https://minerva‐‐1fe2‐5f6d‐9fcb‐b4ff5d944857 (viewed Aug 2022).
  • 6. Martin HL, Ohara K, Chin W, et al. Cancer services in Western Australia: a comparison of regional outcomes with metropolitan Perth. Aust J Rural Health 2015; 23: 302‐308.
  • 7. Beith J, Burslem K, Bell R, et al. Hormone receptor positive, HER2 negative metastatic breast cancer: a systematic review of the current treatment landscape. Asia Pac J Clin Oncol 2016; 12: 3‐18.
  • 8. Hölzel D, Eckel R, Bauerfeind I, et al. Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post‐metastatic survival: 35‐year results from the Munich Cancer Registry. J Cancer Res Clin Oncol 2017; 143: 1701‐1712.
  • 9. Dawson G, Madsen LT, Dains JE. Interventions to manage uncertainty and fear of recurrence in female breast cancer survivors: a review of the literature. Clin J Oncol Nurs 2016; 20: E155‐E161.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.